In the US and around the globe, populations face a serious but unmet need for new drugs to protect against potentially catastrophic emerging viral pathogens and biological weapons of mass destruction. SIGA Technologies is a pharmaceutical company specializing in developing therapeutic solutions for some of the most lethal pathogens – variola (smallpox), Ebola, dengue, Lassa fever and other dangerous viruses. Our business is to discover and develop drugs to prevent and treat these high-priority threats. Our mission is to create robust, modern countermeasures to dreaded viral diseases.

The company has developed a discovery platform that has shown promise with many pathogens. The process relies on the use of high-throughput screening (HTS) and chemi-informatic systems to identify lead candidates.

With strong working relationships with the Department of Health and Human Services (HHS) (including the National Institutes of Health (NIH), the Biomedical Advanced Research and Development Authority (BARDA), the Centers for Disease Control and Prevention (CDC), and the US Food and Drug Administration (FDA)), the Department of Defense (DoD) and other federal agencies, SIGA believes it is a leading biodefense drug development company today.